From the Journals

2024–2025 Drug Updates in Solid Tumors

Share

On October 24, 2025, Dr. Kevin Y. Chen presented key updates on new drug therapies for solid tumors at JADPRO Live in National Harbor, Maryland. The session highlighted advancements in the treatment of breast, lung, and ovarian cancers, emphasizing the significance of understanding targeted therapies and antibody-drug conjugates' mechanisms of action to manage potential side effects. Notably discussed were treatments for NRG1 fusion-positive tumors, low-grade serous ovarian cancer, and various newly approved targeted therapies that aim to improve quality of life in patients.

Original Source(s)

2024–2025 Drug Updates in Solid Tumors

  • by Kevin Y. Chen, PharmD, MS, BCOP, CPP

  • February 27, 2026

  • 13 min

Related Content

The Most Sensitive Cancer Blood Test Yet

A CRISPR-powered light sensor detected trace amounts of cancer biomarkers in the blood

  • February 24, 2026

  • 2 min
Baptist Health Miami Cancer Institute Names Bruna Pellini, M.D., Chief of Thoracic Medical Oncology

Board-certified thoracic oncologist Bruna Pellini, M.D., has been named chief of thoracic medical oncology at Baptist Health Miami Cancer Institute.

  • by

  • February 6, 2026

  • 3 min
The Role of Human Leukocyte Antigens in Reducing Lung Cancer Risk

With findings that human leukocyte antigen-II (HLA-II) heterozygosity is associated with reduced risk of developing lung cancer, with particular benefits to smokers, Mount Sinai researchers add evidence to the theory of the immune system's protective function against cancer.

  • by

  • February 5, 2025

  • 1 min